Warner Pharmaceutical

Warner Pharmaceutical is a pharmaceutical manufacturer listed on the STAR Market of the Shanghai Stock Exchange (stock code: 688799), with R&D innovation as its guiding principle and high-end chemical drugs and traditional Chinese medicine research, development, production, and sales as its main business. The company adheres to the corporate mission of "Serving Health through Science and Technology" and follows the business philosophy of "Dedicated to Pharmaceuticals, Honest in Dealing with People," focusing single-mindedly on expanding its core business. It has progressively established a R&D system covering everything from new product ideation, research, and registration to industrialization, and has built three production bases: a chemical API base, a chemical drug formulation base, and a botanical extract raw material and proprietary Chinese medicine base, distributed across the Wangcheng Economic Development Zone and the Liuyang Economic Development Zone in Hunan. It also maintains a distribution network that broadly covers tertiary hospitals, primary healthcare institutions, and OTC terminals. This has formed two complete industrial chains—"from chemical APIs to chemical drug formulations" and "from traditional Chinese medicine pre-processing, extraction, and separation to proprietary Chinese medicines"—with continuously strengthened internal collaboration and supporting capabilities between R&D and industrialization. Through collaborative platforms such as postdoctoral workstations, industry-university-research joint laboratories, and a chiral drug engineering center, the company has achieved close cooperation with scientific research institutions including Central South University, Hunan University, and the Beijing Institute of Pharmacology of the Chinese Academy of Medical Sciences, thereby advancing the initiation and development of innovative drugs, improved new drugs, and generic drugs. The six core technology platforms, exemplified by bismuth preparations and pellets, continue to accumulate high-end talent, technology, and products, maintaining a leading level of new drug development projects. With coordinated development across R&D, production, and sales, revenue and profits have maintained rapid and stable growth. In the future, the company will strengthen its talent recruitment, training, reserve, and incentive strategies, continuously improve the performance evaluation and internal promotion mechanisms for R&D technical personnel, professional management staff, and market service personnel, and build a clear, transparent internal talent development pathway to progressively optimize the age and professional structure of its core talent. Thus, with abundant human resource reserves, the company aims to establish marketing service advantages in market segments through its product cluster strengths, and build cost and quality advantages in integrated APIs and formulations through its technological and product integration strengths, creating a first-class domestic high-end chemical drug industrialization platform with international market competitiveness. It will also leverage distinctive traditional Chinese medicines, such as substitutes for endangered animal medicinal materials and botanical extract raw materials, as entry points to build a specialized innovative traditional Chinese medicine industrialization platform. The company is committed to becoming a branded, reputable, and trustworthy supplier of health products.